These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 19995848)

  • 1. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R; Kinsella K; Duggan M; Jordan S; Hutchinson M; Tubridy N
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
    Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
    Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
    J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
    Motamed MR; Najimi N; Fereshtehnejad SM
    Clin Neurol Neurosurg; 2007 May; 109(4):344-9. PubMed ID: 17300863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmet needs of multiple sclerosis patients in the community.
    Lonergan R; Kinsella K; Fitzpatrick P; Duggan M; Jordan S; Bradley D; Hutchinson M; Tubridy N
    Mult Scler Relat Disord; 2015 Mar; 4(2):144-50. PubMed ID: 25787190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
    Kobelt G; Texier-Richard B; Lindgren P
    Mult Scler; 2009 Jun; 15(6):741-51. PubMed ID: 19383645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
    Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
    J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and quality of life of multiple sclerosis in Sweden.
    Berg J; Lindgren P; Fredrikson S; Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.